Four weeks of near-normalization of blood glucose has no effect on postprandial GLP-1 and GIP secretion, but augments pancreatic B-cell responsiveness to a meal in patients with Type 2 diabetes

被引:50
|
作者
Hojberg, P. V. [1 ,2 ]
Vilsboll, T. [2 ]
Zander, M. [1 ]
Knop, F. K. [2 ]
Krarup, T. [2 ]
Volund, A. [3 ]
Holst, J. J. [4 ]
Madsbad, S. [1 ]
机构
[1] Univ Copenhagen, Hvidovre Hosp, Dept Endocrinol, DK-2650 Hvidovre, Denmark
[2] Univ Copenhagen, Gentofte Hosp, Dept Internal Med F, DK-1168 Copenhagen, Denmark
[3] Univ Copenhagen, Novo Nordisk AS, Dept Biostat, DK-1168 Copenhagen, Denmark
[4] Univ Copenhagen, Panum Inst, Dept Med Physiol, DK-1168 Copenhagen, Denmark
关键词
B-cell function; glucagon-like peptide-1; glucose-dependent insulinotropic polypeptide; meal response; Type 2 diabetes mellitus;
D O I
10.1111/j.1464-5491.2008.02579.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective The aim of the present study was to investigate whether 4 weeks of near-normalization of blood glucose (BG) improves incretin hormone secretion and pancreatic B-cell function during a mixed meal. Research design and methods Nine patients with Type 2 diabetes in poor glycaemic control [glycated haemoglobin (HbA(1c)) 8.0 +/- 0.4%] were investigated before and after 4 weeks of near-normalization of BG (mean BG 6.4 +/- 0.3 mmol/l) using insulin treatment. HbA(1c) after insulin treatment was 6.6 +/- 0.3%. For comparison, nine healthy control subjects were also studied. Postprandial glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) incremental responses were assessed during a mixed meal test. Fasting and postprandial pancreatic B-cell function was determined from calculations of insulin secretion rates in relation to plasma glucose. Results There was no difference in IAUC(totalGLP-1) or in IAUC(totalGIP) between the two experimental days. B-cell sensitivity to glucose (insulinogenic index) did not differ before and after insulin treatment in the fasting state (0.21 +/- 0.17 vs. 0.25 +/- 0.10 pmol kg(-1) min(-1)/mmol l(-1)), but improved significantly during the first 30 min after start of the meal (0.28 +/- 0.07 vs. 0.46 +/- 0.06 pmol kg(-1) min(-1)/mmol l(-1)) and during the following 4 h (0.34 +/- 0.09 vs. 0.56 +/- 0.07 pmol kg-1 min-1/mmol l(-1)). The B-cell responsiveness to changes in plasma glucose, expressed as the slope of the linear relationship between the insulin secretion rate and the concomitant plasma glucose increased from 0.59 +/- 0.16 to 0.94 +/- 0.13 pmol kg-1 min-1/mmol l(-1) ( P < 0.07). Conclusions Four weeks of near-normalization of BG had no effect on postprandial secretion of incretin hormones. Nevertheless, several parameters of meal-induced insulin secretion improved after insulin treatment.
引用
收藏
页码:1268 / 1275
页数:8
相关论文
共 27 条
  • [11] Effect of GLP-1 and GIP on C-peptide secretion after glucagon or mixed meal tests: Significance in assessing B-cell function in diabetes
    Guglielmi, C.
    Del Toro, R.
    Lauria, A.
    Maurizi, A. R.
    Fallucca, S.
    Cappelli, A.
    Angeletti, S.
    Lachin, J. M.
    Pozzilli, P.
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2017, 33 (06)
  • [12] Near normalisation of blood glucose improves the secretion of amylin during GLP-1 potentiation of glucose-induced insulin secretion in patients with type 2 diabetes
    Asmar, M.
    Hojberg, P.
    Holst, J.
    Madsbad, S.
    DIABETOLOGIA, 2008, 51 : S256 - S256
  • [13] Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes
    Nauck, MA
    El-Ouaghlidi, A
    Gabrys, B
    Hücking, K
    Holst, JJ
    Deacon, CF
    Gallwitz, B
    Schmidt, WE
    Meier, JJ
    REGULATORY PEPTIDES, 2004, 122 (03) : 209 - 217
  • [14] Enhancement of B-cell secretion by blood glucose normalization in type 2 diabetes is associated with fasting C-peptide levels
    Clauson, P
    Alvarsson, M
    Grill, V
    JOURNAL OF INTERNAL MEDICINE, 1997, 241 (06) : 493 - 500
  • [15] META-ANALYSIS OF THE EFFECT OF DUAL GIP AND GLP-1 RECEPTOR AGONISTS ON BLOOD PRESSURE LEVELS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
    Patoulias, Dimitrios
    Katsimardou, Alexandra
    Boulmpou, Aristi
    Imprialos, Konstantinos
    Stavropoulos, Konstantinos
    Toumpourleka, Maria
    Papadopoulos, Christodoulos
    Karagiannis, Asterios
    Doumas, Michael
    JOURNAL OF HYPERTENSION, 2022, 40 (SUPPL) : E300 - E301
  • [16] ENDOGENOUS GLP-1 LEVEL BUT NOT WEIGHT REDUCTION PREDICTS EFFECT OF LIRAGLUTIDE 3,0 MG ON BLOOD GLUCOSE NORMALIZATION IN PATIENTS WITH OBESITY AND TYPE 2 DIABETES
    Sklyanik, I.
    Shestakova, E.
    Shestakova, M.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2021, 23 : A163 - A163
  • [17] Eight weeks of treatment with long-acting GLP-1 analog taspoglutide improves postprandial insulin secretion and sensitivity in metformin-treated patients with type 2 diabetes
    Gastaldelli, Amalia
    Nauck, Michael A.
    Balena, Raffaella
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2013, 62 (09): : 1330 - 1339
  • [18] Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus
    Vilsboll, T.
    Brock, B.
    Perrild, H.
    Levin, K.
    Lervang, H. -H.
    Kolendorf, K.
    Krarup, T.
    Schmitz, O.
    Zdravkovic, M.
    Le-Thi, T.
    Madsbad, S.
    DIABETIC MEDICINE, 2008, 25 (02) : 152 - 156
  • [19] The effect of eight weeks' treatment with the short-acting GLP-1 agonist, lixisenatide, on postprandial blood pressure and heart rate in patients with type two diabetes - A secondary quantitative study
    Lu, A.
    Bound, M.
    Wu, T.
    Blefari, C.
    Horowitz, M.
    Rayner, C.
    Jones, K.
    INTERNAL MEDICINE JOURNAL, 2022, 52 : 39 - 40
  • [20] Ly3437943 (LY), a novel triple GIP/GLP-1/glucagon receptor agonist, provides glucose lowering and weight loss in patients with type 2 diabetes after 12 weeks of treatment
    Milicevic, Z.
    Urva, S.
    Loh, M.
    Coskun, T.
    Du, Y.
    Benson, C. T.
    Loghin, C.
    Haupt, A.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S58 - S59